XBiotechXBIT
About: XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-inflammatory therapeutic antibodies as a treatment for cancer. Geographically, all of its operations are in the United States.
Employees: 92
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
3.61% less ownership
Funds ownership: 14.69% [Q1] → 11.08% (-3.61%) [Q2]
7% less funds holding
Funds holding: 55 [Q1] → 51 (-4) [Q2]
17% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 18
31% less capital invested
Capital invested by funds: $14.5M [Q1] → $10M (-$4.48M) [Q2]
42% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 19
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $3K
Research analyst outlook
We haven’t received any recent analyst ratings for XBIT.
Financial journalist opinion









